A kind of synthetic method of Cagrilintide
Through Fmoc solid phase strategy and specific amino acid coupling reaction, the synthesis process of Cagrilintide is simplified, the problems of complex operation and high cost in the existing technology are solved, high purity and high yield are achieved, and large-scale production is suitable for production, which is expanded. Application prospects.
Patent Information
- Application Number
- CN202111615700.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-12-27
AI Technical Summary
The existing Cagrilintide synthesis method has complex operation, low reaction rate, high cost, and difficult to adapt to large-scale production. Its purity and yield are insufficient, which limits its application prospects.
Using the Fmoc solid phase strategy, the coupling reaction is performed by selecting specific amino acids of the Cagrilintide sequence as pseudopropidin dipeptide, combining Rink Amide AM resin and deprotection reagent, and performing step-by-step coupling, cleavage and cyclization treatment, simplifying operations and improving Reaction rate.
It realizes the high purity and high yield of Cagrilintide, reduces production costs, is suitable for large-scale production, has significant economic and practical value and wide application prospects.
Smart Images

Figure CN114249808B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of polypeptide drug synthesis, in particular to a method for synthesizing Cagrilintide. Background Art
[0002] English name: Cagrilintide.
[0003] The peptide sequence is:
[0004] Eicosanedioic acidγ-Glu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser -Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2(Disulfide bridge:Cys4-Cys9)
[0005] Cagrilintide, an amylin analog being developed by Novo Nordisk, has previously been shown to be effective in the treatment of obesity in Phase 2 clinical trials. Cagrilintide is a long-acting amylin analog with a half-life of about 7-8 days. Compared with pramlintide (an amylin analog with a very short plasma half-life, which must therefore be injected 2-3 times a day), the half-life is significantly improved. WO2010046357 and WO2009034119 disclose polypeptides (referred to as amylin derivatives) comprising amylin analogs with albumin binding residues. Even though these polypeptides with albumin binding moieties show improved pharmacokinetic (PK) or pharmacodynamic (PD) properties compared to pramlintide, they may still show poor physical stability under certain conditions. Amylin is another hormone associated with hunger and satiety, outside of the GLP-1 signaling pathway. Cagrilintide can reduce energy intake, regulate food choices and preferences, and is secreted together with insulin to play a glucose regulation role, inhibit postprandial glucagon release, and delay gastric emptying. It has obvious advantages in the treatment of diabetes, obesity, metabolic syndrome, and cardiovascular diseases, and has a wide range of application prospects. The market needs a synthesis method of Cagrilintide with simple reaction operation, high reaction rate, low cost, and suitable for large-scale production. The present invention solves such problems. Summary of the invention
[0006] In order to solve the deficiencies of the prior art, the object of the present invention is to provide a method for synthesizing Cagrilintide. The method for synthesizing Cagrilintide has the advantages of simple operation, high reaction rate, low cost, being suitable for large-scale production, high purity and yield, and considerable economic and practical value and broad application prospects.
[0007] In order to achieve the above object, the present invention adopts the following technical solution:
[0008] A method for synthesizing Cagrilintide comprises the following steps:
[0009] Step 1, selecting the 7th-8th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, the 10th-11th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st-22nd amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ser-Ser(pro-me-me)-OH;
[0010] Step 2: According to the amino acid sequence Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro- OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser-Ser(pro-me-me)-OH, Fmoc-His(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)- OH, Fmoc-Cys(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu-OtBu, Eicosanedioic acid performs the following coupling reaction:
[0011] After Rink AmideAM resin was swollen by adding DCM, the solvent was drained and washed, and a deprotection reagent was added to remove Fmoc, and the indene test result was positive; the activated Fmoc-Pro-OH, HOBt, and DIC mixed solution was added for reaction, and the indene test result was negative, and then the coupling reaction was completed by draining and washing; the amino resin, Fmoc-Pro-OH, HOBt, and DIC mixed solution were in the molar ratio range of 1:2-4:2.2-4.4:2.2-4.4;
[0012] After the coupling is completed, the Cagrilintide peptide resin is obtained after washing and drying;
[0013] Step 3, adding the fully protected peptide to a cleavage reagent, and obtaining the Cagrilintide peptide after precipitation and drying;
[0014] Step 4: Cyclize the crude linear peptide with a cyclizing agent and a Vc reagent, and then filter to obtain a crude Cagrilintide product.
[0015] The above-mentioned synthesis method of Cagrilintide, the coupling reaction is specifically as follows: weigh 5.71g of Rink AmideAM resin (resin substitution degree is 0.35mmol / g) and add it to a solid phase reactor, add 50mL DCM to swell the resin for 0.5h; drain the solvent, add 50mL DMF solution to wash several times, and drain the solvent; add 50mL deprotection reagent to remove Fmoc for 30 minutes, the temperature does not exceed 20 degrees Celsius, add DMF 50mL to wash several times, and the indene test result is positive; weigh Fmoc-Pro-OH 5.03g, HOBt 1.13g, DIC 1.2mL, add DMF 20mL to dissolve, and activate in an ice bath for 10min; add the activated solution to the reactor, react for 1h, and after the indene test result is negative, drain; add DMF to wash several times, 200mL each time.
[0016] In the aforementioned synthesis method of Cagrilintide, the deprotection reagent is a mixture of piperidine and DMF, and the mixture of piperidine and DMF consists of 20% by mass of piperidine and 80% by mass of DMF.
[0017] The aforementioned synthesis method of Cagrilintide, step three, prepare 200mL of cleavage reagent, add the fully protected peptide under ice bath conditions, return to room temperature after 0.5h and continue to react for 2h, after the reaction is completed, add anhydrous ether to precipitate, centrifuge the precipitation multiple times, add 300mL of ether each time, and the product obtained after drying is the Cagrilintide peptide.
[0018] In the aforementioned method for synthesizing Cagrilintide, the cleavage reagent is TFA:EDT:TIS:H2O in a volume ratio of 87.5:5:2.5:5.
[0019] In the aforementioned synthesis method of Cagrilintide, the specific steps of cyclization in step 4 include: dissolving the crude linear peptide in acetonitrile aqueous solution at a dosage of 1 g of crude linear peptide in 100 mL of 50% acetonitrile aqueous solution, and adding purified water to dilute the linear peptide to 1 g / L after the linear peptide is dissolved; adding a cyclization reagent until the cyclization liquid is microscopically yellow and stirring for about 5 minutes without fading the color, and adding an appropriate amount of Vc reagent until the cyclization liquid is clear and colorless.
[0020] In the aforementioned synthesis method of Cagrilintide, the cyclization reagent is prepared by dissolving 30-40 mL of ethanol per gram of iodine.
[0021] In the aforementioned synthesis method of Cagrilintide, the Vc reagent is prepared by dissolving each gram of Vc in 20-30 mL of purified water.
[0022] In the aforementioned method for synthesizing Cagrilintide, the filtration in step 4 is microporous membrane filtration.
[0023] The present invention is beneficial in that:
[0024] The present invention adopts the Fmoc solid phase strategy to synthesize Cagrilintide, and uses a dipeptide fragment to replace the commonly used amino acid coupling method one by one; the reaction operation is simple, the reaction rate is high, the cost is low, and it is suitable for large-scale production;
[0025] The present invention finds that the 7th to 8th amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, the 10th to 11th amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st to 22nd amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ser-Ser(pro-me-me)-OH. The three have a synergistic effect in improving the purity and yield of Cagrilintide.
[0026] The Cagrilintide obtained by the method of the invention has high purity and yield, and has considerable economic and practical value and broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is the chromatogram result diagram of Example 1 of the present invention;
[0028] Figure 2 It is the chromatogram result figure of comparative example 1 of the present invention;
[0029] Figure 3 It is the chromatogram result figure of comparative example 2 of the present invention. DETAILED DESCRIPTION
[0030] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0031] Example 1: Preparation of Cagrilintide peptide resin with 7-8Fmoc-Ala-Thr(pro-me-me)-OH, 10-11Fmoc-Ala-Thr(pro-me-me)-OH, 21-22Fmoc-Ser-Ser(pro-me-me)-OH:
[0032] The 7th and 8th amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, the 10th and 11th amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st and 22nd amino acids of the Cagrilintide sequence are used as the pseudo-pro dipeptide Fmoc-Ser-Ser(pro-me-me)-OH;
[0033] Weigh 5.71g of Rink AmideAM resin (resin substitution degree is 0.35mmol / g) and add it to the solid phase reactor, add 50mL DCM to swell the resin for 0.5h. Drain the solvent, add 50mL DMF solution to wash three times, and drain the solvent. Add 50mLv / v20% piperidine / DMF to remove Fmoc for 30 minutes, the temperature does not exceed 20 degrees Celsius, add 50mL DMF to wash 6 times. The indene test result is positive. Weigh Fmoc-Pro-OH 5.03g, HOBt 1.13g, DIC1.2mL, add DMF20mL to dissolve, and activate in an ice bath for 10min. Add the activated solution to the reactor, react for 1h, and drain after the indene test result is negative. Add DMF and wash 3 times, 200mL each time. It should be noted that the numerical values here are only examples, and any mixture of amino resin, Fmoc-Pro-OH, HOBt, and DIC in a molar ratio of 1:2-4:2.2-4.4:2.2-4.4 is applicable to the present invention. Here, v / v 20% piperidine / DMF is a mixture consisting of 20% piperidine by mass and 80% DMF by mass, which is only a deprotection reagent, and other deprotection reagents may also be selected, such as 1% DBU / DMF solution (DBU is 1,8-diazacyclo[5,4,0]-7-undecene), 5% piperazine / DMF solution.
[0034] Repeat the above steps and follow the amino acid sequence Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pr o-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser-Ser(pro-me-me)-OH, Fmoc-His(Trt)-OH , Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)- OH, Fmoc-Cys(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu-OtBu, Eicosanedioic acid performs the coupling reaction. After the coupling was completed, DCM and methanol were washed alternately for 3 times, 400 mL each time, and vacuum dried to obtain Cagrilintide peptide resin.
[0035] Lysis:
[0036] Prepare 200mL of cleavage reagent with a volume ratio of TFA:EDT:TIS:H2O = 87.5:5:2.5:5, add the fully protected peptide under ice bath conditions, return to room temperature after 0.5h and continue to react for 2h. After the reaction is completed, add anhydrous ether for precipitation. Centrifuge the precipitation 4 times, adding 300mL of ether each time. The product obtained after drying is the Cagrilintide peptide, and the peptide is 9.24g.
[0037] Cyclization:
[0038] 1) Preparation of cyclization reagent: Dissolve 1 gram of iodine in 30-40 mL of ethanol
[0039] 2) Preparation of Vc reagent: Dissolve each gram of Vc in 20-30 mL of purified water
[0040] 3) Cyclization: Dissolve the crude linear peptide in 20% acetonitrile aqueous solution (1g crude linear peptide is dissolved in 100mL 50% acetonitrile aqueous solution). After the linear peptide is dissolved, add purified water to dilute to 1g / L. Add the cyclization reagent until the cyclization solution turns slightly yellow. Stir for about 5 minutes and the color does not fade. Add an appropriate amount of Vc reagent until the cyclization solution is clear and colorless.
[0041] 4) Post-treatment: After the cyclization is completed, the crude Cagrilintide is obtained by filtering with a microporous filter membrane.
[0042] The purified freeze-dried powder was 3.18 g, with an estimated yield of 40.76% and a purity of 97.55%.
[0043] Purification analysis method: C18 column
[0044] gradient:
[0045] Mobile phase: MPA: 0.1% TFA
[0046] MPB:95% acetonitrile
[0047] The results of the graph are shown in the figure Figure 1 shown.
[0048] Comparative Example 1: Preparation of peptide resin by 10-11Fmoc-Ala-Thr(pro-me-me)-OH, 21-22Fmoc-Ser-Ser(pro-me-me)-OH Cagrilintide:
[0049] The 10th and 11th amino acids of the Cagrilintide sequence are used as the pseudo-proline dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st and 22nd amino acids of the Cagrilintide sequence are used as the pseudo-proline dipeptide Fmoc-Ser-Ser(pro-me-me)-OH
[0050] Weigh 2.85g of Rink AmideAM resin (Sub = 0.35mmol / g) and add it to a solid phase reactor. Add 25mL of DCM to swell the resin for 0.5h. Drain the solvent, add 25mL of DMF solution to wash three times, and drain the solvent. Add 25mL v / v 20% piperidine / DMF to remove Fmoc for 30 minutes, the temperature does not exceed 20 degrees Celsius, and add 25mL of DMF to wash 6 times. The indene test result is positive. Weigh Fmoc-Pro-OH 2.80g, HOBt 1.13g, DIC1.2mL, add DMF20mL to dissolve, and activate in an ice bath for 10min. Add the activated solution to the reactor, react for 1h, and drain after the indene test result is negative. Add DMF and wash 3 times, 200mL each time.
[0051] Repeat the above steps and follow the amino acid sequence Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-P ro-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser-Ser(pro-me-me)-OH, Fmoc-His(Trt)- OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-Thr(pro-me-m e)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Thr-OH, Fmoc-Ala-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu-OtBu, Eicosanedioic Acid 1 performs the coupling reaction. After the coupling was completed, DCM and methanol were washed alternately for 3 times, 400 mL each time, and vacuum dried to obtain Cagrilintide peptide resin.
[0052] Lysis
[0053] Prepare 100 mL of cleavage reagent with a volume ratio of TFA:EDT:TIS:H2O = 87.5:5:2.5:5, add the fully protected peptide under ice bath conditions, return to room temperature after 0.5 h and continue to react for 2 h. After the reaction is completed, add anhydrous ether for precipitation. Centrifuge the precipitation 4 times, adding 150 mL of ether each time. The product obtained after drying is the Cagrilintide peptide, and the peptide is 4.16 g.
[0054] Cyclization
[0055] 1) Preparation of cyclization reagent: Dissolve 1 gram of iodine in 30-40 mL of ethanol
[0056] 2) Preparation of Vc reagent: Dissolve each gram of Vc in 20-30 mL of purified water
[0057] 3) Cyclization: Dissolve the crude linear peptide in 20% acetonitrile aqueous solution (1g crude linear peptide is dissolved in 100mL 50% acetonitrile aqueous solution). After the linear peptide is dissolved, add purified water to dilute to 1g / L. Add the cyclization reagent until the cyclization solution turns slightly yellow. Stir for about 5 minutes and the color does not fade. Add an appropriate amount of Vc reagent until the cyclization solution is clear and colorless.
[0058] 4) Post-treatment: After the cyclization is completed, the crude Cagrilintide is obtained by filtering with a microporous filter membrane.
[0059] The purified freeze-dried powder was 1.31 g, with an estimated yield of 33.5% and a purity of 96.75%.
[0060] Purification analysis method: C18 column
[0061] gradient:
[0062] Mobile phase: MPA: 0.1% TFA
[0063] MPB: 95% acetonitrile.
[0064] Spectrum Figure 2 shown.
[0065] Comparative Example 2: Preparation of Cagrilintide Peptide Resin by 7-8Fmoc-Ala-Thr(pro-me-me)-OH, 21-22Fmoc-Ser-Ser(pro-me-me)-OH:
[0066] The 7th and 8th amino acids of the Cagrilintide sequence are used as the pseudo-proline dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st and 22nd amino acids of the Cagrilintide sequence are used as the pseudo-proline dipeptide Fmoc-Ser-Ser(pro-me-me)-OH
[0067] Weigh 2.85g of Rink AmideAM resin (resin substitution degree is 0.35mmol / g) and add it to the solid phase reactor, add 50mL DCM to swell the resin for 0.5h. Drain the solvent, add 50mL DMF solution to wash three times, and drain the solvent. Add 50mL v / v 20% piperidine / DMF to remove Fmoc for 30 minutes, the temperature does not exceed 20 degrees Celsius, and add 50mL DMF to wash 6 times. The indene test result is positive. Weigh Fmoc-Pro-OH 2.80g, HOBt 1.13g, DIC1.2mL, add DMF20mL to dissolve, and activate in an ice bath for 10min. Add the activated solution to the reactor, react for 1h, and drain after the indene test result is negative. Add DMF and wash 3 times, 200mL each time.
[0068] Repeat the above steps and follow the amino acid sequence Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pr o-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser-Ser(pro-me-me)-OH, Fmoc-His(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala -OH, Fmoc-Cys(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu-OtBu, Eicosanedioic acid
[0069] After the coupling reaction, the mixture was washed alternately with DCM and methanol for 3 times, 400 mL each time, and dried under vacuum to obtain Cagrilintide peptide resin.
[0070] Lysis:
[0071] Prepare 100 mL of cleavage reagent with a volume ratio of TFA:EDT:TIS:H2O = 87.5:5:2.5:5, add the fully protected peptide under ice bath conditions, return to room temperature after 0.5 h and continue to react for 2 h. After the reaction is completed, add anhydrous ether for precipitation. Centrifuge the precipitation 4 times, adding 150 mL of ether each time. The product obtained after drying is the Cagrilintide peptide, and the peptide is 4.23 g.
[0072] Cyclization:
[0073] 1) Preparation of cyclization reagent: Dissolve 1 gram of iodine in 30-40 mL of ethanol
[0074] 2) Preparation of Vc reagent: Dissolve each gram of Vc in 20-30 mL of purified water
[0075] 3) Cyclization: Dissolve the crude linear peptide in 20% acetonitrile aqueous solution (1g crude linear peptide is dissolved in 100mL 50% acetonitrile aqueous solution). After the linear peptide is dissolved, add purified water to dilute to 1g / L. Add the cyclization reagent until the cyclization solution turns slightly yellow. Stir for about 5 minutes and the color does not fade. Add an appropriate amount of Vc reagent until the cyclization solution is clear and colorless.
[0076] 4) Post-treatment: After the cyclization is completed, the crude Cagrilintide is obtained by filtering with a microporous filter membrane.
[0077] The purified freeze-dried powder was 1.36 g, with an estimated yield of 34.8% and a purity of 97.06%.
[0078] Purification analysis method: C18 column
[0079] gradient:
[0080] Mobile phase: MPA: 0.1% TFA
[0081] MPB:95% acetonitrile
[0082] Spectrum Figure 3 shown.
[0083] From the experimental results of Example 1 and Comparative Examples 1 and 2, it can be seen that the present invention uses the 7th-8th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, the 10th-11th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st-22nd amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ser-Ser(pro-me-me)-OH, and the three have a synergistic effect in improving the purity and yield of Cagrilintide.
[0084] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.
Claims
1. A method for synthesizing Cagrilintide, It is characterized in that The steps are as follows: Step 1, selecting the 7th-8th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, the 10th-11th amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ala-Thr(pro-me-me)-OH, and the 21st-22nd amino acids of the Cagrilintide sequence as the pseudo-pro dipeptide Fmoc-Ser-Ser(pro-me-me)-OH; Step 2: According to the amino acid sequence Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser(tBu)-OH , Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Pro-OH , Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ser-Ser(pro-me-me)-OH, Fmoc-His(Trt)-OH, Fmoc-Arg(Pbf)-OH , Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ala-Thr(pro-me -me)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Ala-Thr(pro-me-me)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Glu-OtBu and Eicosanedioic acid perform the following coupling reaction: Weigh 5.71g of Rink AmideAM resin and add it to a solid phase reactor, add 50mL of DCM to swell the resin for 0.5h; drain the solvent, add 50mL of DMF solution to wash several times, and drain the solvent; add 50mL of deprotection reagent to remove Fmoc for 30 minutes, the temperature does not exceed 20 degrees Celsius, add 50mL of DMF to wash several times, and the indene test result is positive; weigh Fmoc-Pro-OH 5.03g, HOBt 1.13g, DIC1.2mL, add DMF20mL to dissolve, and activate in an ice bath for 10min; add the activated solution to the reactor, react for 1h, and drain after the indene test result is negative; Add DMF to wash several times, 200 mL each time; After the coupling is completed, the Cagrilintide peptide resin is obtained after washing and drying; The mixed solution of amino resin, Fmoc-Pro-OH, HOBt and DIC has a molar ratio of 1:2-4:2.2-4.4:2.2-4.4; Step 3, adding the fully protected peptide to a cleavage reagent, and obtaining the Cagrilintide peptide after precipitation and drying; Step 4: Cyclize the crude linear peptide with a cyclizing agent and a Vc reagent, and then filter to obtain a crude Cagrilintide product.
2. A method for synthesizing Cagrilintide according to claim 1, It is characterized in that The deprotection reagent is a mixture of piperidine and DMF, and the mixture of piperidine and DMF is composed of 20% by mass of piperidine and 80% by mass of DMF.
3. A method for synthesizing Cagrilintide according to claim 1, It is characterized in that Step 3, prepare 200mL of cleavage reagent, add the fully protected peptide under ice bath conditions, return to room temperature after 0.5h and continue the reaction for 2h. After the reaction is completed, add anhydrous ether to precipitate, centrifuge the precipitation several times, add 300mL of ether each time, and the product obtained after drying is the Cagrilintide peptide.
4. A method for synthesizing Cagrilintide according to claim 1 or 3, It is characterized in that The cleavage reagent is TFA: EDT: TIS: H 2 O volume ratio = 87.5:5:2.5:
5.
5. A method for synthesizing Cagrilintide according to claim 1, It is characterized in that The specific steps of the cyclization in step 4 include: dissolving the crude linear peptide in acetonitrile aqueous solution at a dosage of 1 g of crude linear peptide in 100 mL of 50% acetonitrile aqueous solution, and adding purified water to dilute the linear peptide to 1 g / L after the linear peptide is dissolved; adding a cyclization reagent dropwise until the cyclization solution is slightly yellow and stirring for about 5 minutes without fading the color, and adding an appropriate amount of Vc reagent dropwise until the cyclization solution is clear and colorless.
6. A method for synthesizing Cagrilintide according to claim 1 or 5, It is characterized in that The cyclization reagent is prepared by dissolving 30-40 mL of ethanol per gram of iodine.
7. A method for synthesizing Cagrilintide according to claim 1 or 5, It is characterized in that The Vc reagent is prepared by dissolving each gram of Vc in 20-30 mL of purified water.
8. A method for synthesizing Cagrilintide according to claim 1, It is characterized in that The filtration in step 4 is microporous membrane filtration.
Citation Information
Cited By
Method for synthesizing Cagrilintide by large-fragment SPPS-LPPS mixing method
CN119350469A
Method for synthesizing Cagrilintide by large fragment SPPS-LPPS hybrid method
CN119350469B
Synthetic method of canagliptide
CN119661685A
